EUVIMEDEUVIMED entdecken
Leserbrief

Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”

Congxiao Wang, Hujun Wang iD

Circulation · 04.08.2026 · 154 (5)

DOI: 10.1161/circulationaha.126.080024 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Circulation, erschienen am 04.08.2026. Verfasst von Congxiao Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Hujun Wang

Zitieren

APA

Wang, C., & Wang, H. (2026). Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation, 154(5). https://doi.org/10.1161/circulationaha.126.080024

Vancouver

Wang C, Wang H. Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation. 2026;154(5). doi:10.1161/circulationaha.126.080024

BibTeX
@article{Wang2026,
  author = {Wang, Congxiao and Wang, Hujun},
  title = {Letter by Wang and Wang Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {5},
  doi = {10.1161/circulationaha.126.080024}
}
Kostenlos starten →